- Szerzők: Túri Gergő and the European Hospital Vaccine Effectiveness Group
- Megjelenés: 2024.07.26, Influenza and other respiratory viruses
- URL: https://onlinelibrary.wiley.com/doi/10.1111/irv.13360
- MTMT azonosító: 35179813
Absztrakt: We conducted a multicentre test-negative case–control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14–29 days and 40% at 60–105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.